Skip to main content

Call for Papers - Clinical translation of targeted proteomics

Guest Editors:

Tiannan Guo: Westlake University, China
Ed Nice: Monash University, Australia
Stephen Pennington: UCD Conway Institute, Ireland
Henry Rodriguez: National Institutes of Health, USA

Submission Status: Open   |   Submission Deadline: 31 October 2023

Clinical Proteomics is calling for submissions to our Collection on Clinical translation of targeted proteomics.

Meet the Guest Editors

Back to top

Tiannan Guo: Westlake University, China
New Content ItemTiannan Guo is an associate professor at Westlake University. He also leads the iMarker lab at Westlake Laboratory. His research focuses on proteomic technological development and AI-empowered applications in disease diagnosis and therapeutics. He and colleagues developed pressure-cycling technology coupled with SWATH/DIA mass spectrometry to enable effective proteomic analysis of biopsy tissues. His team reported the first proteomic and metabolic profiles of COVID-19 sera, the first proteomic landscape for COVID-19 autopsies, and the first proteomic classifier for diagnosing thyroid nodules. More in

Ed Nice: Monash University, Australia
New Content ItemEd Nice is a Professor at Monash University where he is Head of Clinical Biomarker Discovery and Validation and scientific advisor to the Monash Antibody Technologies Facility, for which he was director from 2009 to 2013. He is also a Visiting Professor at Sichuan University/West China Hospital. His long-term research interests have been in protein and peptide micropurification, biomarker discovery and validation, SPR analysis, high throughput monoclonal antibody production and validation, and clinical biomarker assay development, with a strong translational focus on colorectal cancer, especially the field of faecal proteomics for colorectal cancer detection and surveillance. He is actively involved in the Human Proteome Organization (HUPO).

Stephen Pennington: UCD Conway Institute, Ireland
New Content ItemStephen Pennington graduated from Imperial College of Science and Technology (Imperial College London) with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge.  His research team in University College Dublin is currently focused on the translation of novel protein biomarkers to clinical diagnostic tests. He founded the UCD spin out company, Atturos in late 2016 and was awarded UCD's Innovator of the Year in 2018. Steve is currently Professor of Proteomics and Senior Fellow, UCD Conway Institute, President of the British Society of Proteome Research, and past President of HUPO. Most recently, he and a rheumatologist colleague are leading an IMI funded European consortium (HIPPOCRATES; which seeks to address key unmet needs in Psoriatic Disease.

Henry Rodriguez: National Institutes of Health, USA
New Content ItemHenry Rodriguez is the Founding Director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute, National Institutes of Health. Recently, he served as Assistant Director for Strategic Health and Cancer Science, in the Executive Office of the President at the White House. A cell and molecular biologist with a background in business, Dr. Rodriguez’s biomedical research has focused on mechanisms of cancer in basic and clinical science, and the development of measurement science, standards, and technology. Dr. Rodriguez has authored more than 150 original research papers, including co-editing a best-selling book on oxidative stress and aging.


About the collection

Accurate and rapid performance of medical diagnostic tests is a critical requirement for molecular diagnosis and disease treatment. While immunoassays are used in the majority of in vitro diagnostics, limitations such as cross-reactivity, low sensitivity, and limited dynamic range, compel clinical laboratories to seek better solutions that are highly sensitive, reproducible and specific, while also providing high throughput.

Recent advancements in new analytical methods and techniques over the last decade, specifically mass spectrometry (MS)-based targeted proteomic analytical methods and techniques, now allow for the highly reproducible and precise measurement of nearly every human protein. Nevertheless, translating these methods and techniques into ‘clinical grade’ assays presents many challenges.

We invite submissions for this special issue that focuses on the clinical translation of targeted MS proteomics and associated technologies. The scope includes, but is not limited to, the areas listed below:

• MS-based targeted proteomics methodologies, such as selected/multiple reaction monitoring (S/MRM) and parallel reaction monitoring (PRM). The reported methods could be MS hardware- or software-based.
• MS-based targeted proteomics assay resources.
• Development, testing, and validation of targeted assays for measuring protein expression, post-translational modifications (PTMs) and protein functions to aid in the diagnosis and/or monitoring of human diseases.
• Standardization of targeted proteomics methodologies for clinical applications, such as MS data acquisition, data formats, quality control, internal and external standards, metrological analysis, and other clinical translation issues. 
• Non-MS-based targeted proteomics with clinical potential.

Research articles, technical notes, reviews, and commentaries are all examples of article types.

  1. Mass spectrometry (MS) assays offer exceptional capabilities in high multiplexity, specificity, and throughput. As proteomics technologies continue advancements to identify new disease biomarkers, transition o...

    Authors: Chia-Li Han, Chi-Ting Lai, Aaron James Reyes, Hao-Chin Yang, Jin-Ying Lu, Shyang-Rong Shih, Kuen-Yuan Chen, Andrew N. Hoofnagle, Sung-Liang Yu, William Bocik, Tara Hiltke, Huan-Chi Chiu, Ching-Yi Wan, Henry Rodriguez, Victoria Zhang and Yu-Ju Chen
    Citation: Clinical Proteomics 2024 21:12
  2. Dynein axonemal intermediate chain 1 protein (DNAI1) plays an essential role in cilia structure and function, while its mutations lead to primary ciliary dyskinesia (PCD). Accurate quantitation of DNAI1 in lun...

    Authors: Hui Wang, Xiaoyan Ni, Nicholas Clark, Kristen Randall, Lianne Boeglin, Sudha Chivukula, Caroline Woo, Frank DeRosa and Gang Sun
    Citation: Clinical Proteomics 2024 21:8
  3. Routine measurement of cancer biomarkers is performed for early detection, risk classification, and treatment monitoring, among other applications, and has substantially contributed to better clinical outcomes...

    Authors: Deborah Wenk, Charlotte Zuo, Thomas Kislinger and Lusia Sepiashvili
    Citation: Clinical Proteomics 2024 21:6
  4. The 2022 consensus statement of the European Atherosclerosis Society (EAS) on lipoprotein(a) (Lp(a)) recognizes the role of Lp(a) as a relevant genetically determined risk factor and recommends its measurement...

    Authors: Nina M. Diederiks, L. Renee Ruhaak, Fred P. H. T. M. Romijn, Mervin M. Pieterse, Nico P. M. Smit and Christa M. Cobbaert
    Citation: Clinical Proteomics 2024 21:5
  5. Ovarian cancer is the most lethal gynecologic malignancy in women, and high-grade serous ovarian cancer (HGSOC) is the most common subtype. Currently, no clinical test has been approved by the FDA to screen th...

    Authors: Joohyun Ryu, Kristin L. M. Boylan, Carly A. I. Twigg, Richard Evans, Amy P. N. Skubitz and Stefani N. Thomas
    Citation: Clinical Proteomics 2024 21:1
  6. Histones posttranslational modification represent an epigenetic mechanism that regulate gene expression and other cellular processes. Quantitative mass spectrometry used for the absolute quantification of such...

    Authors: Katarzyna Macur, Andrew Schissel, Fang Yu, Shulei Lei, Brenda Morsey, Howard S. Fox and Pawel Ciborowski
    Citation: Clinical Proteomics 2023 20:48
  7. Quantification of drug-target binding is critical for confirming that drugs reach their intended protein targets, understanding the mechanism of action, and interpreting dose-response relationships. For covale...

    Authors: Andrew G. Chambers, David C. Chain, Steve M. Sweet, Zifeng Song, Philip L. Martin, Matthew J. Ellis, Claire Rooney and Yeoun Jin Kim
    Citation: Clinical Proteomics 2023 20:47
  8. Glioblastoma is one of the most malignant primary brain cancer. Despite surgical resection with modern technology followed by chemo-radiation therapy with temozolomide, resistance to the treatment and recurren...

    Authors: Narae Kang, Hyun Jeong Oh, Ji Hye Hong, Hyo Eun Moon, Yona Kim, Hyeon-Jeong Lee, Hophil Min, Hyeonji Park, Sang Hun Lee, Sun Ha Paek and Jonghwa Jin
    Citation: Clinical Proteomics 2023 20:45

    The Correction to this article has been published in Clinical Proteomics 2024 21:9

  9. Meningiomas are the most prevalent primary brain tumors. Due to their increasing burden on healthcare, meningiomas have become a pivot of translational research globally. Despite many studies in the field of d...

    Authors: Ankit Halder, Deeptarup Biswas, Aparna Chauhan, Adrita Saha, Shreeman Auromahima, Deeksha Yadav, Mehar Un Nissa, Gayatri Iyer, Shashwati Parihari, Gautam Sharma, Sridhar Epari, Prakash Shetty, Aliasgar Moiyadi, Graham Roy Ball and Sanjeeva Srivastava
    Citation: Clinical Proteomics 2023 20:41

Submission Guidelines

Back to top

Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select Clinical translation of targeted proteomics from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.